Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506883 | 0.89 | P2RX7 (0.60) | P2RX7 | |
| SCHEMBL4492302 | 0.84 | P2RX7 (0.67) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL4498495 | 0.80 | P2RX7 (0.67) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL4504565 | 0.80 | P2RX7 (0.62) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL4497111 | 0.79 | P2RX7 (0.61) | P2RX7 | |
| SCHEMBL4501549 | 0.79 | P2RX7 (0.59) | P2RX7LMNASMN1; SMN2 | |
| SCHEMBL4507223 | 0.79 | P2RX7 (0.58) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL4510035 | 0.79 | P2RX7 (0.73) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL6484063 | 0.78 | P2RX7 (0.62) | P2RX7LMNASMN1; SMN2P2RX3 | |
| SCHEMBL4507143 | 0.78 | P2RX7 (0.57) | P2RX7LMNASMN1; SMN2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 554/4885LMNA 1205/4885SMN1; SMN2 718/4885 |
| US-20050090524-A1 | Novel adamantane derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 732/4885LMNA 1999/4885SMN1; SMN2 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.